英格兰3万份NHS放疗计划心脏和肺部剂量的真实世界审计
结果显示绝大多数计划心脏和肺部剂量达标,但中心间存在差异,尤其在VMAT计划中,提示质量改进空间。
核心结论
- 大规模真实世界剂量审计可行,心脏和肺部剂量总体达标且与国际基准相当,但中心间存在剂量学差异,尤其在VMAT计划中。
关键数值与推荐
- 心脏约束:保乳/胸壁/部分乳腺计划平均心脏剂量<2 Gy;含内乳链计划平均心脏剂量<6 Gy。
临床怎么用
- 常规乳腺癌放疗中绝大多数计划心脏和肺部剂量可达标,可参考国家评分卡进行中心间比较和质量改进。
- VMAT在内乳链计划中广泛应用且靶区覆盖更优,但需关注其平均心脏剂量较高的现象并优化计划。
局限性
- 仅纳入英格兰NHS中心,结果外推需谨慎。
- 计划上传按治疗类型分层,可能存在选择偏倚。
- 未报告临床结局,剂量学差异的临床意义尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Around 57 000 people are diagnosed with breast cancer annually in the UK. Radiotherapy can improve local control and survival, but it can also cause long-term side-effects. UK hypofractionation trials have defined dose constraints for heart and lung, reducing heart exposure and treatment burden in a research setting. However, real-world data on heart and lung doses remain scarce. In 2022, the National Health Service (NHS) in England procured a cloud-based radiation dosimetry repository (ProKnow). Using this resource, we aimed to characterise heart and lung doses in routine breast radiotherapy, quantify variation between centres, inform national guidance, and support quality improvement. METHODS: On Dec 11, 2024, NHS England invited all 49 NHS radiotherapy centres in England to upload anonymised radiotherapy plans to ProKnow. Plan upload was stratified by laterality; breast, chest wall, or partial-breast only (26 Gy in five fractions); breast or chest wall and axilla (40 Gy in 15 fractions); and breast or chest wall and axilla and internal mammary chain (40 Gy in 15 fractions). Use of field-based versus volumetric-modulated arc therapy was recorded. Dose-volume heart and lung metrics were analysed against national scorecards derived from UK trials. FINDINGS: Between Dec 11, 2024, and April 24, 2025, 48 of 49 centres participated, contributing 30 582 plans. 27 368 were harvested for analysis, of which 26 236 (95·9%) were analysable. For breast, chest wall, or partial-breast-only treatments, 10 012 (99·8%) of 10 031 left-sided cases and 6961 (99·9%) of 6962 right-sided cases achieved mean heart doses (MHD) below 2 Gy (median MHD 0·57 Gy [IQR 0·43-0·74; left] and 0·25 Gy [0·18-0·36; right]). For nodal plans including internal mammary chain, median MHDs were 3·3 Gy (IQR 2·3-4·5; left) and 2·3 Gy (1·1-3·7; right). 2405 (98·3%) of 2446 plans met the 6 Gy constraint. 8697 (92·1%) of 9448 left-sided breast, chest wall, or partial-breast plans met the optimal lung dose constraint (volume of ipsilateral lung receiving >7·8 Gy being ≤15%) and 1155 (96·0%) of 1203 left-sided nodal-internal mammary chain plans met the mandatory lung dose constraint (volume of lung receiving >17 Gy being ≤35%). Volumetric-modulated arc therapy was used in 65 (0·3%) of 21 119 breast-only plans, 276 (10·5%) of 2638 nodal-non-internal mammary chain plans, and 1738 (70·1%) of 2479 internal mammary chain plans. Volumetric-modulated arc therapy delivered superior target volume coverage but higher MHDs compared to field-based techniques. INTERPRETATION: This breast radiotherapy dosimetry audit shows the feasibility of high-quality large-scale, real-world dosimetric collection and evaluation across the NHS in England. Heart and lung doses predominantly met constraints and were comparable to international benchmarks. However, dosimetric variation existed between centres, particularly in volumetric-modulated arc therapy planning, identifying opportunities for quality improvement. FUNDING: NHS England.
引用
- Kirby AM, Hatton NL, Hansen VN, et al. Real-world heart and lung doses from 30 000 National Health Service radiotherapy treatment plans in England: a national audit of breast radiotherapy practice. Lancet Oncol. 2026. PMID: 42150588. doi:10.1016/S1470-2045(26)00185-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。